Skip to main content

Peer Review reports

From: A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

Original Submission
10 Aug 2018 Submitted Original manuscript
16 Sep 2018 Reviewed Reviewer Report - Janice Dutcher
24 Sep 2018 Reviewed Reviewer Report - Reviewer 2
30 Oct 2018 Author responded Author comments - Jennifer McQuade
Resubmission - Version 2
30 Oct 2018 Submitted Manuscript version 2
1 Nov 2018 Reviewed Reviewer Report - Janice Dutcher
4 Dec 2018 Reviewed Reviewer Report - Reviewer 2
5 Dec 2018 Author responded Author comments - Jennifer McQuade
Resubmission - Version 3
5 Dec 2018 Submitted Manuscript version 3
Publishing
6 Dec 2018 Editorially accepted
19 Dec 2018 Article published 10.1186/s12885-018-5193-9

You can find further information about peer review here.

Back to article page